• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Travere Therapeutics Inc.

    11/14/24 1:01:01 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TVTX alert in real time by email
    SC 13G 1 p24-3059sc13g.htm TRAVERE THERAPEUTICS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.)*
     

    Travere Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    89422G107

    (CUSIP Number)
     

    September 30, 2024

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 6 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 89422G10713GPage 2 of 6 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Woodline Partners LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    4,340,340

    6

    SHARED VOTING POWER

    - 0 -

    7

    SOLE DISPOSITIVE POWER

    4,340,340

    8

    SHARED DISPOSITIVE POWER

    - 0 -

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,340,340

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.7%

    12

    TYPE OF REPORTING PERSON

    IA

             

     

     

    CUSIP No. 89422G10713GPage 3 of 6 Pages

     

    Item 1(a). NAME OF ISSUER.
       
      The name of the issuer is Travere Therapeutics, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 3611 Valley Centre Dr, Suite 300, San Diego, CA 92130.

     

    Item 2(a) NAME OF PERSON FILING:
       
      This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of Common Stock (as defined in Item 2(d) below) directly held by the Woodline Fund.
       
      The filing of this statement should not be construed as an admission that the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111.

     

    Item 2(c). CITIZENSHIP:
       
      Woodline Partners is a Delaware limited partnership.  

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common stock, par value $0.0001 per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      89422G107

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

     

    CUSIP No. 89422G10713GPage 4 of 6 Pages

     

      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution:  _______________________

     

    Item 4. OWNERSHIP.
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for the Reporting Person and is incorporated herein by reference.
       
      The percentage set forth herein is calculated based upon 76,491,485 shares of Common Stock outstanding as of July 29, 2024 as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 1, 2024.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2. The Woodline Fund has right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

     

    CUSIP No. 89422G10713GPage 5 of 6 Pages

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.
       
      The Reporting Person hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 89422G10713GPage 6 of 6 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATED: November 14, 2024

     

    WOODLINE PARTNERS LP
         
         
    By: /s/ Erin Mullen  
    Name: Erin Mullen  
    Title: General Counsel & Chief Compliance Officer  
         

     

    Get the next $TVTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TVTX

    DatePrice TargetRatingAnalyst
    1/10/2025Overweight
    Cantor Fitzgerald
    10/21/2024$9.00 → $27.00Equal Weight → Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    9/9/2024$25.00Neutral → Buy
    Guggenheim
    3/27/2024Buy → Neutral
    Guggenheim
    12/5/2023$7.00 → $10.00Neutral → Buy
    Citigroup
    11/20/2023$7.00Neutral
    Citigroup
    9/22/2023$24.00 → $8.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $TVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.

      SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)

      11/14/24 5:13:38 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Travere Therapeutics Inc.

      SC 13G - Travere Therapeutics, Inc. (0001438533) (Subject)

      11/14/24 1:01:01 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.

      SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)

      11/14/24 9:46:28 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

      Meissa Vaccines ("Meissa"), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, Ph.D., cofounder of Meissa, will serve as the Company's Chief Scientific Officer. "I am excited to welcome Frank to the Meissa leadership team," said Dr. Moore. "We are at an important stage in Meissa's growth, and Frank brings extensive, complementary experience in commercial planning, business developm

      7/11/22 8:00:00 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

      Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J

      3/23/22 7:30:00 AM ET
      $ATRA
      $NTRA
      $TVTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities
      Biotechnology: Pharmaceutical Preparations
    • Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer

      SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) in 2022, as well as the continued advancement of its pegtibatinase program in classical homocystinuria (HCU). "We are excited to welcome Jula to the Travere Therapeutics

      1/4/22 4:30:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Financials

    Live finance-specific insights

    See more
    • Travere Therapeutics Reports First Quarter 2025 Financial Results

      Submitted sNDA seeking full approval of FILSPARI® (sparsentan) for FSGS in March 2025 U.S. net product sales of FILSPARI totaled $55.9 million in 1Q 2025; 703 new PSFs received in the period FILSPARI was recently converted to full approval for the treatment of IgAN in Europe and the UK Clinical data presented at the National Kidney Foundation Spring Clinical Meetings reinforced FILSPARI's foundational position in IgAN and potential in FSGS Cash, cash equivalents, and marketable securities as of March 31, 2025, totaled $322 million Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its first quarter 2025 financial results and provided a corporate update. "As the only fully approve

      5/1/25 4:01:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics to Report First Quarter 2025 Financial Results

      Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company

      4/24/25 4:30:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics,

      2/13/25 4:30:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Cline Christopher R. converted options into 4,920 shares and sold $37,553 worth of shares (1,784 units at $21.05), increasing direct ownership by 3% to 93,126 units (SEC Form 4)

      4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

      5/5/25 9:54:31 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Dube Eric M converted options into 18,924 shares and sold $398,350 worth of shares (18,924 units at $21.05) (SEC Form 4)

      4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

      5/5/25 9:53:47 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF COMMERCIAL OFFICER Heerma Peter converted options into 4,920 shares and sold $37,280 worth of shares (1,771 units at $21.05), increasing direct ownership by 3% to 128,215 units (SEC Form 4)

      4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

      5/5/25 9:53:07 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Travere Therapeutics to Participate at Upcoming Investor Conferences

      Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2025 Healthcare Conference Presenting on Wednesday, May 14, 2025, at 3:40 p.m. PT Jefferies Global Healthcare Conference Presenting on Wednesday, June 4, 2025, at 3:10 p.m. ET Scotiabank Third Annual Healthcare Canadian Investor Day Tuesday, June 17, 2025 Live webcasts of the BofA Securities 2025 Healthcare Conference and Jefferies Global Healthcare Conference presentations will be accessible on the Investor page of Travere's website at ir.travere.com/events-and-presentations. Replays will be available for up to 30 days followi

      5/7/25 4:30:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics Reports First Quarter 2025 Financial Results

      Submitted sNDA seeking full approval of FILSPARI® (sparsentan) for FSGS in March 2025 U.S. net product sales of FILSPARI totaled $55.9 million in 1Q 2025; 703 new PSFs received in the period FILSPARI was recently converted to full approval for the treatment of IgAN in Europe and the UK Clinical data presented at the National Kidney Foundation Spring Clinical Meetings reinforced FILSPARI's foundational position in IgAN and potential in FSGS Cash, cash equivalents, and marketable securities as of March 31, 2025, totaled $322 million Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its first quarter 2025 financial results and provided a corporate update. "As the only fully approve

      5/1/25 4:01:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

      European Commission converts conditional approval of FILSPARI into standard marketing authorization for the treatment of IgAN EU approval is based on the complete data set from the Phase 3 PROTECT Study The UK's MHRA also converts the conditional approval of FILSPARI to standard approval Travere Therapeutics, Inc., (NASDAQ:TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). Standard MA is gran

      4/29/25 7:01:00 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    SEC Filings

    See more
    • SEC Form 144 filed by Travere Therapeutics Inc.

      144 - Travere Therapeutics, Inc. (0001438533) (Subject)

      5/5/25 11:32:52 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Travere Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K/A - Travere Therapeutics, Inc. (0001438533) (Filer)

      5/1/25 5:21:35 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Travere Therapeutics Inc.

      10-Q - Travere Therapeutics, Inc. (0001438533) (Filer)

      5/1/25 4:47:20 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Travere Therapeutics

      Cantor Fitzgerald initiated coverage of Travere Therapeutics with a rating of Overweight

      1/10/25 9:14:01 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Travere Therapeutics from Equal Weight to Overweight and set a new price target of $27.00 from $9.00 previously

      10/21/24 8:16:27 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Travere Therapeutics

      Scotiabank initiated coverage of Travere Therapeutics with a rating of Sector Outperform

      10/16/24 8:39:33 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care